The cachexia score (CASCO): a new tool for staging cachectic cancer patients.
The cachexia score (CASCO): a new tool for staging cachectic cancer patients.
复制标题
缓存评分（CASCO）：用于分期缓存癌症患者的新工具。
DOI：
10.1007/s13539-011-0027-5
复制
发表时间：
2011-06
期刊：
影响因子：
--
通讯作者：
Busquets S
中科院分区：
文献类型：
--
作者：
Argilés JM;López-Soriano FJ;Toledo M;Betancourt A;Serpe R;Busquets S
根据最近的共识，恶病质综合征被定义为：“…一种与潜在疾病相关的复杂代谢综合征，其特征是肌肉减少，但脂肪量减少或不减少。”恶病质的突出临床特征是成人体重减轻（纠正体液潴留）或儿童生长衰竭（不包括内分泌紊乱）。厌食症、炎症、胰岛素抵抗和肌肉蛋白质分解增加通常与恶病质有关。”虽然这个定义附有诊断标准，但它没有考虑分期问题。在考虑治疗时，患者分层很重要。消瘦综合症的第一阶段并不一定包括体重减轻——一种被称为前恶病质的状态。目前评分的目的是克服癌症患者分期的问题。这个分数考虑了五个主要的不同因素：体重和瘦体重损失；厌食症;炎症、免疫和代谢紊乱；物理性能;以及生活质量。评分范围从0到100分：轻度恶病质（小于25分）、中度恶病质（大于26分，小于50分）、重度恶病质（大于51分，小于75分）、终末期恶病质（大于76分，小于100分）。该评分还考虑了被称为恶病质前的状况。目前的评分将促进恶病质分期，因此将允许更充分的治疗。本文的在线版本（doi:10.1007/s13539-011-0027-5）包含补充材料，授权用户可使用。
According to a recent consensus, the cachectic syndrome is defined as: “… a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders). Anorexia, inflammation, insulin resistance, and increased muscle protein breakdown are frequently associated with cachexia.” Although this definition is accompanied by diagnostic criteria, it does not consider the problem of staging. Stratification of patients is important when considering therapy. The very first stage of the wasting syndrome does not necessarily involve body weight loss—a state known as pre-cachexia. The aim of the present score was to overcome the problem of patient staging in cancer. This score considers five main different factors: body weight and lean body mass loss; anorexia; inflammatory, immunological, and metabolic disturbances; physical performance; and quality of life. The scoring scale goes from 0 to 100: mild cachexia (less than 25), moderate (more than 26 and less than 50), severe (more than 51 and less than 75), and terminal phase (more than 76 and up to 100). The score also takes into consideration the condition known as pre-cachexia. The present score will facilitate cachexia staging and will therefore allow for a more adequate therapy. The online version of this article (doi:10.1007/s13539-011-0027-5) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
4.7
作者：
Mantovani, G;Macciò, A;Serpe, R
通讯作者：
Serpe, R
影响因子：
8.2
作者：
MATTHEWS, DR;HOSKER, JP;TURNER, RC
通讯作者：
TURNER, RC
影响因子：
3.3
作者：
Brunelli, Alessandro;Salati, Michele
通讯作者：
Salati, Michele
影响因子：
3.5
作者：
Barreiro, E;de la Puente, B;Argilés, JM
通讯作者：
Argilés, JM
DOI：
10.1093/jnci/85.5.365
发表时间：
1993-03-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
AARONSON, NK;AHMEDZAI, S;TAKEDA, F
通讯作者：
TAKEDA, F